CLEC5a-directed bispecific antibody for effective cellular phagocytosis

• Main Authors: Vivekananda Kedage (Author), Diego Ellerman (Author), Mingjian Fei (Author), Wei-Ching Liang (Author), Gu Zhang (Author), Eric Cheng (Author), Juan Zhang (Author), Yongmei Chen (Author), Haochu Huang (Author), Wyne P. Lee (Author), Yan Wu (Author), Minhong Yan (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

While antibody-dependent cellular phagocytosis mediated by activating Fcγ receptor is a key mechanism underlying many antibody drugs, their full therapeutic activities can be restricted by the inhibitory Fcγ receptor IIB (FcγRIIB). Here, we describe a bispecific antibody approach that harnesses phagocytic receptor CLEC5A (C-type Lectin Domain Containing 5A) to drive Fcγ receptor-independent phagocytosis, potentially circumventing the negative impact of FcγRIIB. First, we established the effectiveness of such an approach by constructing bispecific antibodies that simultaneously target CLEC5A and live B cells. Furthermore, we demonstrated its in vivo application for regulatory T cell depletion and subsequent tumor regression.

Item Description

10.1080/19420862.2022.2040083
1942-0870
1942-0862